CRTX News and Press, Cortexyme Inc. From 02/16/21

Gainers: Diffusion Pharmaceuticals (DFFN) +36%, Strongbridge Biopharma (SBBP) +25%, KemPharm (KMPH) +20%, Senseonics Holdings (SENS) +17%, ReWalk Robotics (RWLK) +14%.Losers: bluebird bio (BLUE) -32%, Cortexyme (CRTX) -30%, Inhi...

Cortexyme (CRTX) tanks 24% premarket after receiving a letter from the FDA stating that a partial clinical hold has been placed on atuzaginstat (COR388) impacting the open-label extension ((OLE)) phase of the company’s Phase 2/3 study, the GAIN Trial (GingipAIN Inhibitor for ...

bluebird bio (BLUE) -30% after suspending sickle cell disease trial.Hepion Pharmaceuticals (HEPA) -28% after pricing stock offering.Cortexyme (CRTX) -26% after regulatory update on Atuzaginstat in Alzheimer’s Disease.Neptune Wellness Solutions (NEPT) -21%&...

- Double-blind phase of GAIN Trial to continue as planned, with top-line data expected Q4 2021 - Open-Label Extension of atuzaginstat to stop dosing and enrollment Cortexyme, Inc. (NASDAQ: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and ot...

— Chris Lowe Promoted to Chief Operating Officer and Chief Financial Officer — Ted Monohon Promoted to Chief Accounting Officer —Drew Sukovich, Ph.D., RAC, Joins as Vice President, Regulatory and Quality Cortexyme, Inc. (Nasdaq: CRTX), a comp...

Gainers: [[NVAX]] +20.9%. [[SWKS]] +14.8%. [[WDC]] +10.2%. [[SCPS]] +8.9%. [[BBBY]] +8.5%.Losers: [[GSIT]] -20.8%. [[SNDE]] -17.9%. [[STIM]] -4.9%. [[FIZZ]] -4.2%. [[CRTX]] -3.7%. For further details see: NVAX, WDC, GSIT and FIZZ among after-hours movers

Cortexyme ([[CRTX]] +16.8%) says that based on interim analysis of GAIN Trial of its lead candidate atuzaginstat (COR388) in patients with mild-to-moderate Alzheimer's disease, the company announced pipeline expansion for 2021.Atuzaginstat will be evaluated in a new Phase ...

— Based upon successful completion of the GAIN Trial’s interim analysis, pipeline expansion announced for 2021 — Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson’s disease — COR588, a novel lysine gingip...

CRTX thinks that a bacteria causes Alzheimer's, and it has research to back up that hypothesis. A Phase 3 trial will yield toppling data in Dec 2021, and they have enough cash. The risk-reward ratio is high for the molecule, but that's true for any Alzheimer's research. For ...

Cortexyme, Inc. (CRTX) is down -19.4% as Citi initiated coverage on the stock with a ‘Sell’ rating. Noting that risks from ‘company’s “unique” Alzheimer’s disease approach are still not reflected in the stock even after the recen...